A Phase 2 interventional study of Insulin icodec and Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 43 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-05.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.
Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 4 that started in 2019, is one of 3 in phase 2, and was the 9th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Canada, Germany, Italy
Ages 18+
Xi'an International Medical Center Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 205 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 84 across the 27 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 27 have an industry lead sponsor. The 2 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 216th largest by enrollment of the 428 interventional ones that give a count, is one of 29 that started in 2019, is one of 37 in phase 2, and was the 477th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin icodec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07747402Xi'an International Medical Center HospitalInsulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared. This is done to find the best way to change the dose of insulin 287. Participants will either get insulin 287 that they will have to inject once a week or insulin glargine that participants will have to inject once a day. Which treatment participants get is decided by chance. The study will last for about 5 months (23 weeks). Participants will have 14 clinic visits and 6 phone calls with the study doctor. At 3 of the clinic visits participants will be asked not to eat or drink anything (except for water) in the last 8 hours before the visit. During the study, the study doctor will ask participants to:
Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.
Inclusion Criteria:
Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s):
i) DPP4i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose) ii) SGLT2i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose )
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Controlled on metformin with or without DPP4i (dipeptidyl peptidase-4 inhibitors) and with or without SGLT2i (sodium-glucose cotransporter 2 inhibitors).
Drug: Insulin icodec
Controlled on metformin with or without DPP4i and with or without SGLT2i.
Drug: Insulin icodec
Controlled on metformin with or without DPP4i and with or without SGLT2i.
Drug: Insulin icodec
Controlled on metformin with or without DPP4i and with or without SGLT2i.
Drug: Insulin Glargine
Administered subcutaneously SC once weekly. Starting dose will be 70U.
Also known as: Insulin 287
Administered subcutaneously SC once daily.The starting dose will be 10U.
Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring)
The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication). The endpoint is based on data recorded by CGM system. It was required that at least 70% of the planned CGM measurements during weeks 15-16 were available for endpoint data to be included in the analysis.
Time frame: During the last 2 weeks of treatment (week 15 and 16)
Change in HbA1c (Glycated Haemoglobin)
Estimated mean change in HbA1c from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)
Change in Fasting Plasma Glucose (FPG)
Estimated mean change in FPG from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)
Change in Body Weight
Estimated mean change in body weight from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)
Weekly Insulin Dose
Estimated mean average weekly insulin dose during the last 2 weeks of treatment is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
Time frame: During the last 2 weeks of treatment (week 15 and 16)
Number of Treatment Emergent Adverse Events (TEAEs)
A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. The on-treatment observation period was the time period from first dose of trial product (week 0, visit 2) until the follow-up visit (week 21, visit 20) or the last date on trial product + 5 weeks for once daily insulin and +6 weeks for once weekly insulin.
Time frame: From baseline week 0 (visit 2) to week 21 (visit 20)
Number of Severe Hypoglycaemic Episodes (Level 3)
Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of severe hypoglycaemic episodes that occurred from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.
Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter) or Severe Hypoglycaemic Episodes (Level 3)
Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG) meter or severe hypoglycaemic episodes (level 3) that occured from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.
Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)
Number of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter)
Hypoglycaemia alert value (level 1) was defined as episodes that were sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy with plasma glucose value of equal to or above (\>=) 3.0 and \< 3.9 mmol/L (\>= 54 and \< 70 mg/dL) confirmed by BG meter. Number of hypoglycaemic alert episodes (level 1) that occured from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.
Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)
The trial was conducted at 38 sites in 7 countries as follows: Croatia (4), Germany (9), Hungary (3), Poland (4), Slovakia (5), Spain (4), United States (9). In addition, 1 site in Slovakia and 3 sites in the United States screened, but didn't randomise any subjects.
| Milestone | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Started | 51 | 51 | 52 | 51 |
| Full analysis set (fas) | 51 | 51 | 52 | 51 |
| Safety analysis set (sas) | 51 | 51 | 52 | 51 |
| Completed | 50 | 51 | 52 | 51 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication). The endpoint is based on data recorded by CGM system. It was required that at least 70% of the planned CGM measurements during weeks 15-16 were available for endpoint data to be included in the analysis.
| Percentage of time | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring) | 76.65 ± 1.81 | 82.97 ± 1.80 | 80.89 ± 1.81 | 75.89 ± 1.82 |
Estimated mean change in HbA1c from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
| Percentage point of HbA1c | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Change in HbA1c (Glycated Haemoglobin) | -1.00 ± 0.08 | -1.22 ± 0.08 | -1.38 ± 0.08 | -1.02 ± 0.08 |
Estimated mean change in FPG from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
| Millimoles per liter (mmol/L) | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | -2.23 ± 0.17 | -2.42 ± 0.17 | -3.01 ± 0.17 | -2.34 ± 0.17 |
Estimated mean change in body weight from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
| Kilogram (Kg) | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Change in Body Weight | 0.87 ± 0.35 | 1.11 ± 0.35 | 1.25 ± 0.35 | 0.63 ± 0.35 |
Estimated mean average weekly insulin dose during the last 2 weeks of treatment is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).
| Units of insulin (U) | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Weekly Insulin Dose | 142.47 (119.78 to 169.45) | 176.38 (148.30 to 209.78) | 208.90 (175.94 to 248.04) | 145.56 (122.38 to 173.12) |
A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. The on-treatment observation period was the time period from first dose of trial product (week 0, visit 2) until the follow-up visit (week 21, visit 20) or the last date on trial product + 5 weeks for once daily insulin and +6 weeks for once weekly insulin.
| Count of events | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) | 44 | 67 | 58 | 45 |
Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of severe hypoglycaemic episodes that occurred from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.
| Count of events | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Number of Severe Hypoglycaemic Episodes (Level 3) | 0 | 0 | 0 | 0 |
Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG) meter or severe hypoglycaemic episodes (level 3) that occured from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.
| Count of events | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter) or Severe Hypoglycaemic Episodes (Level 3) | 1 | 2 | 8 | 0 |
Hypoglycaemia alert value (level 1) was defined as episodes that were sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy with plasma glucose value of equal to or above (\>=) 3.0 and \< 3.9 mmol/L (\>= 54 and \< 70 mg/dL) confirmed by BG meter. Number of hypoglycaemic alert episodes (level 1) that occured from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.
| Count of events | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Number of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter) | 14 | 20 | 110 | 10 |
Collected over From baseline (week 0) to week 21 Results are based on the safety analysis set which included all participants exposed to at least one dose of trial product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin 287 (Titration Algorithm A) | 0/51 (0%) | 3/51 (5.9%) | 9/51 (17.6%) |
| Insulin 287 (Titration Algorithm B) | 0/51 (0%) | 1/51 (2%) | 10/51 (19.6%) |
| Insulin 287 (Titration Algorithm C) | 0/52 (0%) | 0/52 (0%) | 7/52 (13.5%) |
| Insulin Glargine (Titration Algorithm D) | 0/51 (0%) | 2/51 (3.9%) | 9/51 (17.6%) |
| Event | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| Angina pectorisCardiac disorders | 1/51 | 0/51 | 0/52 | 0/51 |
| Choroid neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/51 | 0/51 | 0/52 | 0/51 |
| ErysipelasInfections and infestations | 0/51 | 1/51 | 0/52 | 0/51 |
| Knee arthroplastySurgical and medical procedures | 0/51 | 0/51 | 0/52 | 1/51 |
| MetastasisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/51 | 0/51 | 0/52 | 0/51 |
| PneumoniaInfections and infestations | 0/51 | 0/51 | 0/52 | 1/51 |
| Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/51 | 0/51 | 0/52 | 0/51 |
| Event | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 5/51 | 7/51 | 2/52 | 6/51 |
| Back painMusculoskeletal and connective tissue disorders | 5/51 | 2/51 | 1/52 | 1/51 |
| HeadacheNervous system disorders | 0/51 | 3/51 | 5/52 | 2/51 |
The full analysis set included all randomised participants.
| Age, Continuous(years) | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) | Total |
|---|---|---|---|---|---|
| Mean | 59.8 ± 9.1 | 61.2 ± 8.0 | 61.4 ± 8.0 | 60.2 ± 8.1 | 60.7 ± 8.3 |
| Sex: Female, Male(Participants) | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) | Total |
|---|---|---|---|---|---|
| Female | 24 | 23 | 24 | 24 | 95 |
| Male | 27 | 28 | 28 | 27 | 110 |
| Ethnicity (NIH/OMB)(Participants) | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 2 | 3 | 12 |
| Not Hispanic or Latino | 49 | 46 | 50 | 48 | 193 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Insulin 287 (Titration Algorithm A) | Insulin 287 (Titration Algorithm B) | Insulin 287 (Titration Algorithm C) | Insulin Glargine (Titration Algorithm D) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 2 | 0 | 0 | 2 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| White | 51 | 49 | 51 | 47 | 198 |
| other | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from May 2019 to primary completion in Dec 2019, 7 months.
Results were first posted in Jan 2021, 1 year after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 7 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin icodec